Edwards Lifesciences (NYSE:EW) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Edwards Lifesciences (NYSE:EW) from a hold rating to a buy rating in a research report released on Saturday,Wall Street Zen reports.

A number of other analysts also recently issued reports on EW. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Citigroup reaffirmed a “buy” rating on shares of Edwards Lifesciences in a report on Monday, October 5th. Evercore restated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. UBS Group restated a “buy” rating on shares of Edwards Lifesciences in a research report on Thursday, October 8th. Finally, Barclays raised shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $86.52 on Friday. Edwards Lifesciences has a 1-year low of $72.67 and a 1-year high of $96.29. The stock has a market cap of $49.82 billion, a price-to-earnings ratio of 49.72, a P/E/G ratio of 2.27 and a beta of 0.87. The stock’s 50-day moving average is $88.44 and its 200 day moving average is $86.33. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The business’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences will post 3.00 EPS for the current fiscal year.

Insider Activity

In other news, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Andrew M. Dahl sold 544 shares of the firm’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 5,045 shares of company stock worth $451,596 over the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Several hedge funds have recently modified their holdings of EW. Hanson & Doremus Investment Management purchased a new position in shares of Edwards Lifesciences during the 1st quarter worth about $25,000. MV Capital Management Inc. acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth about $26,000. RMG Wealth Management LLC purchased a new position in Edwards Lifesciences in the 1st quarter worth approximately $26,000. Pin Oak Investment Advisors Inc. acquired a new stake in Edwards Lifesciences during the 2nd quarter valued at $26,000. Finally, GK Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter valued at about $26,000. 79.46% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.